輝隆股份(002556.SZ):“輝隆定02”10月21日起開始轉股
格隆匯10月20日丨輝隆股份(002556.SZ)公佈,2020年4月21日為“輝隆定02”(債券代碼: 124009)的發行日,中國證券登記結算有限責任公司深圳分公司已完成本次發行的定向可轉換公司債券的登記,本次可轉債的發行對象已正式列入輝隆股份的普通證券賬户持有人名冊。
根據有關規定和《安徽輝隆農資集團股份有限公司發行股份、可轉換公司債券及支付現金購買資產並募集配套資金暨關聯交易報告書》的約定,此次可轉債的轉股期自發行結束之日起滿6個月後第一個交易日起至到期日止。轉股期限即2020年10月21日至2025年4月20日,轉股價為人民幣6.5元/股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.